195 related articles for article (PubMed ID: 35439717)
21. Adenosine A
Waggan I; Rissanen E; Tuisku J; Matilainen M; Parkkola R; Rinne JO; Airas L
Parkinsonism Relat Disord; 2023 Aug; 113():105766. PubMed ID: 37480614
[TBL] [Abstract][Full Text] [Related]
22. Cortical thinning across Parkinson's disease stages and clinical correlates.
Wilson H; Niccolini F; Pellicano C; Politis M
J Neurol Sci; 2019 Mar; 398():31-38. PubMed ID: 30682518
[TBL] [Abstract][Full Text] [Related]
23. Progression of grey and white matter brain damage in Parkinson's disease: a critical review of structural MRI literature.
Sarasso E; Agosta F; Piramide N; Filippi M
J Neurol; 2021 Sep; 268(9):3144-3179. PubMed ID: 32378035
[TBL] [Abstract][Full Text] [Related]
24. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility.
Martin-Bastida A; Lao-Kaim NP; Loane C; Politis M; Roussakis AA; Valle-Guzman N; Kefalopoulou Z; Paul-Visse G; Widner H; Xing Y; Schwarz ST; Auer DP; Foltynie T; Barker RA; Piccini P
Eur J Neurol; 2017 Feb; 24(2):357-365. PubMed ID: 27982501
[TBL] [Abstract][Full Text] [Related]
25. Linking Stage-Specific Plasma Biomarkers to Gray Matter Atrophy in Parkinson Disease.
Lin WC; Lee PL; Lu CH; Lin CP; Chou KH
AJNR Am J Neuroradiol; 2021 Aug; 42(8):1444-1451. PubMed ID: 34045303
[TBL] [Abstract][Full Text] [Related]
26. Gray Matter Atrophy in Parkinson's Disease and the Parkinsonian Variant of Multiple System Atrophy: A Combined ROI- and Voxel-Based Morphometric Study.
Cui X; Li L; Yu L; Xing H; Chang H; Zhao L; Qian J; Song Q; Zhou S; Dong C
Clinics (Sao Paulo); 2020; 75():e1505. PubMed ID: 32555945
[TBL] [Abstract][Full Text] [Related]
27. Clinical and Cerebral Metabolic Changes in Parkinson's Disease With Basal Forebrain Atrophy.
Gang M; Baba T; Hosokai Y; Nishio Y; Kikuchi A; Hirayama K; Hasegawa T; Aoki M; Takeda A; Mori E; Suzuki K
Mov Disord; 2020 May; 35(5):825-832. PubMed ID: 31971293
[TBL] [Abstract][Full Text] [Related]
28. Olfaction, cholinergic basal forebrain degeneration, and cognition in early Parkinson disease.
Barrett MJ; Murphy JM; Zhang J; Blair JC; Flanigan JL; Nawaz H; Dalrymple WA; Sperling SA; Patrie J; Druzgal TJ
Parkinsonism Relat Disord; 2021 Sep; 90():27-32. PubMed ID: 34348192
[TBL] [Abstract][Full Text] [Related]
29. Cognitive and motor correlates of grey and white matter pathology in Parkinson's disease.
Dadar M; Gee M; Shuaib A; Duchesne S; Camicioli R
Neuroimage Clin; 2020; 27():102353. PubMed ID: 32745994
[TBL] [Abstract][Full Text] [Related]
30. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.
Ray NJ; Bradburn S; Murgatroyd C; Toseeb U; Mir P; Kountouriotis GK; Teipel SJ; Grothe MJ
Brain; 2018 Jan; 141(1):165-176. PubMed ID: 29228203
[TBL] [Abstract][Full Text] [Related]
31. Brain volumetry in Parkinson's disease with and without dementia: where are the differences?
Lee SH; Kim SS; Tae WS; Lee SY; Lee KU; Jhoo J
Acta Radiol; 2013 Jun; 54(5):581-6. PubMed ID: 23474765
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease.
Thomas GEC; Hannaway N; Zarkali A; Shmueli K; Weil RS
Mov Disord; 2024 Mar; 39(3):546-559. PubMed ID: 38173297
[TBL] [Abstract][Full Text] [Related]
33. Frontal and subcortical contribution to visual hallucinations in dementia with Lewy bodies and Parkinson's disease.
Pezzoli S; Cagnin A; Antonini A; Venneri A
Postgrad Med; 2019 Sep; 131(7):509-522. PubMed ID: 31422718
[No Abstract] [Full Text] [Related]
34. Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease.
Petrou M; Davatzikos C; Hsieh M; Foerster BR; Albin RL; Kotagal V; Müller ML; Koeppe RA; Herman WH; Frey KA; Bohnen NI
Acad Radiol; 2016 May; 23(5):577-81. PubMed ID: 26874576
[TBL] [Abstract][Full Text] [Related]
35. Considering total intracranial volume and other nuisance variables in brain voxel based morphometry in idiopathic PD.
Crowley S; Huang H; Tanner J; Zhao Q; Schwab NA; Hizel L; Ramon D; Brumback B; Ding M; Price CC
Brain Imaging Behav; 2018 Feb; 12(1):1-12. PubMed ID: 28070745
[TBL] [Abstract][Full Text] [Related]
36. Hierarchical cluster analysis of multimodal imaging data identifies brain atrophy and cognitive patterns in Parkinson's disease.
Inguanzo A; Sala-Llonch R; Segura B; Erostarbe H; Abos A; Campabadal A; Uribe C; Baggio HC; Compta Y; Marti MJ; Valldeoriola F; Bargallo N; Junque C
Parkinsonism Relat Disord; 2021 Jan; 82():16-23. PubMed ID: 33227683
[TBL] [Abstract][Full Text] [Related]
37. Regional volumetric change in Parkinson's disease with cognitive decline.
Gee M; Dukart J; Draganski B; Wayne Martin WR; Emery D; Camicioli R
J Neurol Sci; 2017 Feb; 373():88-94. PubMed ID: 28131236
[TBL] [Abstract][Full Text] [Related]
38. The pattern of gray matter atrophy in Parkinson's disease differs in cortical and subcortical regions.
Lewis MM; Du G; Lee EY; Nasralah Z; Sterling NW; Zhang L; Wagner D; Kong L; Tröster AI; Styner M; Eslinger PJ; Mailman RB; Huang X
J Neurol; 2016 Jan; 263(1):68-75. PubMed ID: 26486354
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers of Parkinson's disease: Striatal sub-regional structural morphometry and diffusion MRI.
Khan AR; Hiebert NM; Vo A; Wang BT; Owen AM; Seergobin KN; MacDonald PA
Neuroimage Clin; 2019; 21():101597. PubMed ID: 30472168
[TBL] [Abstract][Full Text] [Related]
40. Cross-sectional and longitudinal associations between total and regional white matter hyperintensity volume and cognitive and motor function in Parkinson's disease.
Pozorski V; Oh JM; Okonkwo O; Krislov S; Barzgari A; Theisen F; Sojkova J; Bendlin BB; Johnson SC; Gallagher CL
Neuroimage Clin; 2019; 23():101870. PubMed ID: 31150958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
